Aaron L. Ellenbogen

5.1k citations
50 papers · 3.6k · 4 hit papers · h-index 22

Impact in

  • Neurology top 1%
    • Parkinson's Disease Mechanisms and Treatments
    • Neuroinflammation and Neurodegeneration Mechanisms
    • Neurological disorders and treatments
    • Dementia and Cognitive Impairment Research

Papers in

    • Parkinson's Disease Mechanisms and Treatments 31
    • Botulinum Toxin and Related Neurological Disorders 6
    • Neurological disorders and treatments 3
    • Restless Legs Syndrome Research 5

Aaron L. Ellenbogen

47 papers receiving 3.5k citations

Aaron L. Ellenbogen's Hit Papers

Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial 2024 · 59 citations
590+1+2Years since publication5001k1.5k

Peers

Aaron L. Ellenbogen
Comparison fields: 5 of 90
  • Neurology 1.3k
  • Psychiatry and Mental health 879
  • Physiology 1.1k
  • Neurology 163
  • Epidemiology 213
Replace Omid Omidvar with:
Omid Omidvar United States
Elizabeth L. Peckham United States
James P. Sutton United States
Pinky Agarwal United States
Ira J. Goodman United States
Michael A. G. Jonsson Sweden
Akio Kikuchi Japan
Peter McAllister United States
Denis S. Crimmins Australia
Nicola Tambasco Italy
Aaron L. Ellenbogen relative to Omid Omidvar United States Omid Omidvar's profile →
Citations per field
00.5×2×3×
Omid Omidvar · 1×
Citations per year

Countries citing papers authored by Aaron L. Ellenbogen

Since Specialization
Citations

This map shows the geographic impact of Aaron L. Ellenbogen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron L. Ellenbogen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron L. Ellenbogen more than expected).

Fields of papers citing papers by Aaron L. Ellenbogen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron L. Ellenbogen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron L. Ellenbogen. The network helps show where Aaron L. Ellenbogen may publish in the future.

Co-authors

The 25 scholars most cited alongside Aaron L. Ellenbogen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Aaron L. Ellenbogen Line = papers co-authored together Aaron L. Ellenbogen links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Donanemab in Early Symptomatic Alzheimer Disease
Hit paper breakdown →
20231799
2 2018258
3
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease
Hit paper breakdown →
2022183
4 2019166
5 2021104
6 200996
7 201189
8 201680
9 201463
10 200962
11
Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial
Hit paper breakdown →
202459
12
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study
Hit paper breakdown →
202459
13 200958
14 202048
15 201142
16 201941
17 201238
18 201938
19 202137
20 202335

About Aaron L. Ellenbogen

Aaron L. Ellenbogen is a scholar working on Neurology, Epidemiology, Cardiology and Cardiovascular Medicine, Pharmacology and Pediatrics, Perinatology and Child Health, having authored 50 papers that have together received 3.6k indexed citations. Recurring topics across this work include Parkinson's Disease Mechanisms and Treatments (31 papers), Botulinum Toxin and Related Neurological Disorders (6 papers), Restless Legs Syndrome Research (5 papers), Neurological disorders and treatments (3 papers), Atrial Fibrillation Management and Outcomes (2 papers), Pharmacogenetics and Drug Metabolism (1 paper), Alzheimer's disease research and treatments (1 paper) and Dementia and Cognitive Impairment Research (1 paper). The work is most often cited by research in Neurology (1.3k citations), Psychiatry and Mental health (879 citations), Physiology (1.1k citations), Neurology (163 citations) and Epidemiology (213 citations). Aaron L. Ellenbogen has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include Philip M. Becker, Robert A. Hauser, Clete A. Kushida, Ronald W. Barrett, Ira J. Goodman, Beth Safirstein, Stuart Isaacson, Fabrizio Stocchi, Suneel Gupta and Ann Hsu. Their work appears in journals such as Neurology, Clinical Neuropharmacology, Parkinsonism & Related Disorders, Movement Disorders and JAMA Neurology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact